Amicus Therapeutics, Inc.
FOLD
Classifica tra le azioni
#3709
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Prezzo delle azioni
$14.49
Ultima sincronizzazione: 2026-04-27
Capitalizzazione di mercato
$4.55B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
80.22%
Paese
US
Scambia Amicus Therapeutics, Inc. (FOLD)
Categoria
Healthcare
EPS per Amicus Therapeutics, Inc. (FOLD)
EPS al December 2025 TTM: $-0.09
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Amicus Therapeutics, Inc., l’EPS attuale della società (TTM) è $-0.09. Alla fine del 2023, la società aveva un EPS di $-0.51 una diminuzione rispetto a rispetto a quello del 2022, che era di $-0.82.
Storico EPS per Amicus Therapeutics, Inc. da 2003 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-0.09 | -50.83% |
| 2024 | $-0.18 | -64.71% |
| 2023 | $-0.51 | -37.80% |
| 2022 | $-0.82 | -10.87% |
| 2021 | $-0.92 | -14.02% |
| 2020 | $-1.07 | -27.70% |
| 2019 | $-1.48 | -21.28% |
| 2018 | $-1.88 | 1.62% |
| 2017 | $-1.85 | 24.16% |
| 2016 | $-1.49 | 24.17% |
| 2015 | $-1.20 | 29.03% |
| 2014 | $-0.93 | -19.83% |
| 2013 | $-1.16 | 8.41% |
| 2012 | $-1.07 | -16.41% |
| 2011 | $-1.28 | -35.35% |
| 2010 | $-1.98 | 582.76% |
| 2009 | $-0.29 | -83.43% |
| 2008 | $-1.75 | -43.73% |
| 2007 | $-3.11 | -95.06% |
| 2006 | $-62.97 | 29.33% |
| 2005 | $-48.69 | 70.01% |
| 2004 | $-28.64 | 30.12% |
| 2003 | $-22.01 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -19,670.62% |
US
|
|
| $-7.98 | 8,916.95% |
US
|
|
| $-5.29 | 5,877.40% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -31,444.63% |
NL
|
